open access
XANTUS, a prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation
open access
Abstract
XANTUS is the first large, international prospective study to describe rivaroxaban use in a broad patient population with non-valvular atrial fibrillation. Out of 6784 patients, over 96% patients receiving rivaroxaban did not experience any of the outcomes of stroke/systemic embolism, treatment-emergent major bleeding or all-cause death. In XANTUS, rivaroxaban demonstrated low rates of stroke/ systemic embolism and major bleeding, including intracranial and gastrointestinal bleeding. Treatment persistence and patient satisfaction were high, namely 80% of patients remained on rivaroxaban and 75% reported they were satisfied with their treatment at one year.
Abstract
XANTUS is the first large, international prospective study to describe rivaroxaban use in a broad patient population with non-valvular atrial fibrillation. Out of 6784 patients, over 96% patients receiving rivaroxaban did not experience any of the outcomes of stroke/systemic embolism, treatment-emergent major bleeding or all-cause death. In XANTUS, rivaroxaban demonstrated low rates of stroke/ systemic embolism and major bleeding, including intracranial and gastrointestinal bleeding. Treatment persistence and patient satisfaction were high, namely 80% of patients remained on rivaroxaban and 75% reported they were satisfied with their treatment at one year.
Keywords
anticoagulants, atrial fibrillation, rivaroxaban, stroke, thromboembolism
About this articleTitle
XANTUS, a prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation
Journal
Kardiologia Polska (Polish Heart Journal)
Issue
Pages
71-75
Published online
2015-11-25
Page views
293
Article views/downloads
725
DOI
10.5603/KP.2015.0220
Keywords
anticoagulants
atrial fibrillation
rivaroxaban
stroke
thromboembolism
Authors
Marek Postuła
Dariusz Kosior
